Skandinaviska Enskilda Banken (SEB)’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $11.4M | Sell |
23,000
-23,000
| -50% | -$10.2M | 0.43% | 22 |
|
|
2026
Q1 | $20.5M | Sell |
46,000
-128,466
| -74% | -$59.9M | 0.47% | 23 |
|
|
2025
Q4 | $79.1M | Buy |
174,466
+20,218
| +13% | +$8.71M | 0.32% | 60 |
|
|
2025
Q3 | $60.4M | Sell |
154,248
-22,356
| -13% | -$9.34M | 0.24% | 70 |
|
|
2025
Q2 | $78.6M | Sell |
176,604
-9,867
| -5% | -$4.55M | 0.34% | 56 |
|
|
2025
Q1 | $90.4M | Buy |
186,471
+15,437
| +9% | +$7.19M | 0.45% | 40 |
|
|
2024
Q4 | $68.3M | Sell |
171,034
-14,251
| -8% | -$6.61M | 0.31% | 55 |
|
|
2024
Q3 | $86.2M | Sell |
185,285
-33,548
| -15% | -$16.1M | 0.4% | 45 |
|
|
2024
Q2 | $103M | Sell |
218,833
-46,090
| -17% | -$20M | 0.49% | 35 |
|
|
2024
Q1 | $111M | Buy |
264,923
+21,185
| +9% | +$8.96M | 0.54% | 32 |
|
|
2023
Q4 | $99.3M | Sell |
243,738
-82,892
| -25% | -$30.6M | 0.57% | 29 |
|
|
2023
Q3 | $114M | Sell |
326,630
-50,316
| -13% | -$17.6M | 0.75% | 22 |
|
|
2023
Q2 | $133M | Sell |
376,946
-67,057
| -15% | -$22.6M | 0.87% | 19 |
|
|
2023
Q1 | $140M | Buy |
444,003
+37,469
| +9% | +$11.2M | 0.98% | 17 |
|
|
2022
Q4 | $117M | Buy |
406,534
+54,823
| +16% | +$16.7M | 0.88% | 18 |
|
|
2022
Q3 | $102M | Buy |
351,711
+98,458
| +39% | +$28.3M | 0.79% | 22 |
|
|
2022
Q2 | $71.4M | Buy |
253,253
+21,221
| +9% | +$5.68M | 0.52% | 41 |
|
|
2022
Q1 | $60.6M | Sell |
232,032
-55,892
| -19% | -$13.3M | 0.36% | 64 |
|
|
2021
Q4 | $64M | Sell |
287,924
-10,161
| -3% | -$1.98M | 0.33% | 63 |
|
|
2021
Q3 | $54.1M | Sell |
298,085
-8,478
| -3% | -$1.66M | 0.3% | 79 |
|
|
2021
Q2 | $61.8M | Sell |
306,563
-38,644
| -11% | -$8.08M | 0.38% | 58 |
|
|
2021
Q1 | $74.2M | Buy |
345,207
+78,854
| +30% | +$17.3M | 0.49% | 40 |
|
|
2020
Q4 | $63M | Sell |
266,353
-2,326
| -0.9% | -$534K | 0.43% | 52 |
|
|
2020
Q3 | $73.1M | Sell |
268,679
-9,801
| -4% | -$2.7M | 0.53% | 41 |
|
|
2020
Q2 | $80.8M | Buy |
278,480
+105,390
| +61% | +$28.6M | 0.65% | 34 |
|
|
2020
Q1 | $41.2M | Buy |
173,090
+57,812
| +50% | +$13.3M | 0.42% | 52 |
|
|
2019
Q4 | $25.2M | Buy |
115,278
+3,556
| +3% | +$720K | 0.2% | 105 |
|
|
2019
Q3 | $18.9M | Buy |
111,722
+13,493
| +14% | +$2.39M | 0.16% | 127 |
|
|
2019
Q2 | $18M | Sell |
98,229
-8,136
| -8% | -$1.42M | 0.16% | 130 |
|
|
2019
Q1 | $19.6M | Buy |
106,365
+23,809
| +29% | +$4.4M | 0.18% | 118 |
|
|
2018
Q4 | $13.7M | Buy |
82,556
+2,671
| +3% | +$463K | 0.12% | 144 |
|
|
2018
Q3 | $15.4M | Buy |
79,885
+1,200
| +2% | +$214K | 0.12% | 148 |
|
|
2018
Q2 | $13.4M | Buy |
78,685
+10,485
| +15% | +$1.63M | 0.11% | 141 |
|
|
2018
Q1 | $11.1M | Sell |
68,200
-10,331
| -13% | -$1.69M | 0.11% | 133 |
|
|
2017
Q4 | $11.8M | Sell |
78,531
-15,600
| -17% | -$2.31M | 0.1% | 164 |
|
|
2017
Q3 | $14.3M | Sell |
94,131
-13,200
| -12% | -$1.99M | 0.13% | 143 |
|
|
2017
Q2 | $13.8M | Sell |
107,331
-7,800
| -7% | -$939K | 0.13% | 151 |
|
|
2017
Q1 | $12.6M | Sell |
115,131
-7,393
| -6% | -$651K | 0.13% | 154 |
|
|
2016
Q4 | $9.03M | Sell |
122,524
-23,322
| -16% | -$1.9M | 0.11% | 156 |
|
|
2016
Q3 | $12.7M | Buy |
145,846
+2,500
| +2% | +$236K | 0.14% | 124 |
|
|
2016
Q2 | $12.3M | Sell |
143,346
-9,200
| -6% | -$795K | 0.14% | 114 |
|
|
2016
Q1 | $12.1M | Sell |
152,546
-3,500
| -2% | -$317K | 0.14% | 123 |
|
|
2015
Q4 | $19.6M | Buy |
+156,046
| New | +$18.8M | 0.25% | 73 |
|
Other funds holding VRTX
Skandinaviska Enskilda Banken (SEB)'s VRTX Position: Q2 2026 in Review
Skandinaviska Enskilda Banken (SEB) reduced its Vertex Pharmaceuticals (VRTX) stake by 50% in Q2 2026, selling an estimated $10.2M and leaving 23,000 shares worth $11.4M. The position accounts for 0.43% of the portfolio, ranked #22.
Skandinaviska Enskilda Banken (SEB) first reported a position in VRTX in Q4 2015 and has held it in 43 quarters since. The position peaked at $140M in Q1 2023. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Skandinaviska Enskilda Banken (SEB) held 23,000 shares of Vertex Pharmaceuticals worth $11.4M as of Q2 2026.
- Skandinaviska Enskilda Banken (SEB) sold 23,000 Vertex Pharmaceuticals shares in Q2 2026, an estimated $10.2M.
- Vertex Pharmaceuticals made up 0.43% of Skandinaviska Enskilda Banken (SEB)'s portfolio in Q2 2026, its #22 holding.
- Skandinaviska Enskilda Banken (SEB) first reported a position in Vertex Pharmaceuticals in Q4 2015 and has held it in 43 quarters since.
- Skandinaviska Enskilda Banken (SEB)'s Vertex Pharmaceuticals position peaked at $140M in Q1 2023.
- 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q2 2026, filed 10 Aug 2026.